Home › Calculator › ACIU Dividend Calculator 2026
ACIU Dividend DRIP Calculator 2026
75.76% YieldHealthcareAC Immune S.A. · NASDAQ
Price: $2.64 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ACIU pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ACIU snowball 📈
$10,000 in ACIU → $66086426561.64M in 10 years · $5,500,112,225,054,615.00/month
About AC Immune S.A. (ACIU) — Dividend Analysis 2026
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Compare ACIU with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ACIU DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ACIU position with:
🌍 ACIU Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ACIU.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 64.40% | 61.60% | $6,440 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 60.61% | 57.81% | $6,061 / yr |
| 🇬🇧 UK ISA | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇬🇧 UK Taxable | 8.75% | 69.13% | 66.33% | $6,913 / yr |
| 🇨🇦 TFSA | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇨🇦 CA Taxable | 25% | 56.82% | 54.02% | $5,682 / yr |
| 🇦🇺 Super (pension) | 15% | 64.40% | 61.60% | $6,440 / yr |
| 🇦🇺 AU Taxable | 30% | 53.03% | 50.23% | $5,303 / yr |
| 🇩🇪 DE Taxable | 26.375% | 55.78% | 52.98% | $5,578 / yr |
| 🇫🇷 FR Taxable | 30% | 53.03% | 50.23% | $5,303 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ACIU Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ACIU Dividend Payment Schedule
ACIU pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ACIU vs Healthcare Benchmarks
How ACIU compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ACIU sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ACIU Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-11 | 16,568 | — | — | ||
| A-Award | 2026-06-11 | 38,889 | $2.62 | $101.9K | ||
| A-Award | 2026-06-11 | 16,568 | — | — | ||
| A-Award | 2026-06-11 | 38,889 | $2.62 | $101.9K | ||
| A-Award | 2026-06-11 | 77,778 | $2.62 | $203.8K | ||
| A-Award | 2026-06-11 | 33,136 | — | — | ||
| A-Award | 2026-06-11 | 17,751 | — | — | ||
| A-Award | 2026-06-11 | 41,667 | $2.62 | $109.2K | ||
| A-Award | 2026-06-11 | 16,568 | — | — | ||
| A-Award | 2026-06-11 | 38,889 | $2.62 | $101.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ACIU dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
AC Immune S.A. (ACIU) is currently trading at $2.64, 67% below its 52-week high. The current dividend yield is 75.76% based on an annual payout of $2.00 per share.
ACIU (AC Immune S.A.) — 75.76% Dividend Yield Analysis
AC Immune S.A. (ACIU) is a healthcare stock currently trading at $2.64 with a dividend yield of 75.76%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (75.76%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.